...
首页> 外文期刊>Vaccine >A chimeric alphavirus RNA replicon gene-based vaccine for human parainfluenza virus type 3 induces protective immunity against intranasal virus challenge
【24h】

A chimeric alphavirus RNA replicon gene-based vaccine for human parainfluenza virus type 3 induces protective immunity against intranasal virus challenge

机译:一种用于人副流感病毒3型的基于嵌合alphavirus RNA复制子基因的疫苗可诱导针对鼻内病毒攻击的保护性免疫

获取原文
获取原文并翻译 | 示例
           

摘要

Parainfluenza virus type 3 (PIV3) infections continue to be a significant health risk for infants, young children, and immunocompromised adults. We describe a gene-based vaccine strategy against PIV3 using replication-defective alphavirus vectors. These RNA replicon vectors, delivered as virus-like particles and expressing the PIV3 hemagglutinin-neuraminidase glycoprotein, were shown to be highly immunogenic in mice and hamsters, inducing PIV3-specific neutralizing antibody responses. Importantly, the replicon particle-based vaccine administered intramuscularly or intranasally protected against mucosal PIV3 challenge in hamsters, preventing virus replication in both nasal turbinates and lungs. These data suggest that the alphavirus replicon platform can be useful for a PIV3 vaccine and possibly other respiratory viruses.
机译:3型副流感病毒(PIV3)感染仍然是婴儿,幼儿和免疫功能低下的成年人的重大健康风险。我们描述了使用复制缺陷型α病毒载体针对PIV3的基于基因的疫苗策略。这些RNA复制子载体以病毒样颗粒的形式表达并表达PIV3血凝素神经氨酸酶糖蛋白,在小鼠和仓鼠中具有高度免疫原性,可诱导PIV3特异性中和抗体反应。重要的是,肌内或鼻内施用的基于复制子颗粒的疫苗可保护仓鼠免受粘膜PIV3攻击,从而防止病毒在鼻甲和肺中复制。这些数据表明,α病毒复制子平台可用于PIV3疫苗以及可能的其他呼吸道病毒。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号